Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia among Tsimane Forager-Horticulturalists

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 70, Issue 10, 2014, Pages 1262-1268

  Trumble, Benjamin C ^a   Stieglitz, Jonathan ^b,c   Rodriguez, Daniel Eid ^d   Linares, Edhitt Cortez ^d   Kaplan, Hillard S ^b   Gurven, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Institute of Advanced Studies   (France)

^d Tsimane Health and Life History Project   (Bolivia)

Author keywords

Benign prostatic hyperplasia; Evolutionary medicine; Metabolic syndrome; Prostate specific antigen; Testosterone

Indexed keywords

BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGE; AGED; AGRICULTURAL WORKER; BLOOD; BOLIVIA; ECHOGRAPHY; HUMAN; MALE; METABOLISM; MIDDLE AGED; PREVALENCE; PROSTATIC HYPERPLASIA; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; BOLIVIA; FARMERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84944673496     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glv051     Document Type: Article

References (49)

1. Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med. 1995;332:99-109. doi:10.1056/ NEJM199501123320207
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
3. Steiner MS, Couch RC, Raghow S, Stauffer D. The chimpanzee as a model of human benign prostatic hyperplasia. J Urol. 1999;162:1454-1461. doi:10.1016/S0022-5347(05)68340-1
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-2196. doi:10.1016/S0140-6736(12)61729-2
5. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145:405-409.
6. Jin B, Turner L, Walters WA, Handelsman DJ. The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected]. J Clin Endocrinol Metab. 1996;81:4290-4295. doi:10.1210/ jcem.81.12.8954029
7. Andriole G, Bruchovsky N, Chung LWK, et al. Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399-1403. doi:10.1097/01.ju.0000139539.94828.29
8. Kaplan SA, D'Alisera PM. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebocontrolled studies. J Gerontol A Biol Sci Med Sci. 1998;53:M201-M206. doi:10.1093/gerona/53A.3.M201
9. Campbell MF, Wein AJ, Kavoussi LR. Campbell-Walsh Urology/Editorin-Chief, Alan J. Wein ; editors, Louis R. Kavoussi ... [et al.]. 9th ed. Philadelphia: W.B. Saunders; 2012.
10. Park S-G, Choi H-C, Cho B, Kwon Y-M, Kwon H-T, Park J-h. Effect of central obesity on prostate specific antigen measured by computerized tomography: related markers and prostate volume. J Urol. 2012;187:1589-1593. doi:10.1016/j.juro.2011.12.067
11. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2013;189(1 Suppl):S102-S106. doi:10.1016/j. juro.2012.11.029
12. Wolinsky FD, Krygiel J, Wyrwich KW. Hospitalization for Prostate Cancer Among the Older Men in the Longitudinal Study on Aging, 1984-1991. J Gerontol A Biol Sci Med Sci. 2002;57(2):M115M121. doi:10.1093/ gerona/57.2.M115
13. Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol. 2013;189(1 Suppl):S107-S114; discussion S115. doi:10.1016/j.juro.2012.11.026
14. De Nunzio C, William A, Stephen JF, Edward G, Parsons JK. The Correlation Between Metabolic Syndrome and Prostatic Diseases. Eur Urol. 2011;61(3):560-570. doi:10.1016/j.eururo.2011.11.013
15. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562-2568. doi:10.1210/jc.2005-2799
16. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228-1235. doi:10.1016/j.eururo.2008.02.019
17. Gurven M, Kaplan H, Winking J, Eid Rodriguez D, Vasunilashorn S, et al. Inflammation and infection do not promote arterial aging and cardiovascular disease risk factors among lean horticulturalists. PLoS One. 2009;4:e6590. doi:10.1371/journal.pone.0006590
18. Gurven M, Blackwell AD, Rodriguez DE, Stieglitz J, Kaplan H. Does blood pressure inevitably rise with age: longitudinal evidence among foragerhorticulturalists. Hypertension. 2012;60:25-33. doi:10.1161/hypertensionaha. 111.189100
19. Gurven M, Jaeggi AV, Kaplan H, Cummings D. Physical activity and modernization among Bolivian Amerindians. PLoS One. 2013;8:e55679. doi:10.1371/journal.pone.0055679
20. McDade TW, Leonard WR, Burhop J, et al. Predictors of C-reactive protein in Tsimane' 2 to 15 year-olds in lowland Bolivia. Am J Phys Anthropol. 2005;128:906-913. doi:10.1002/ajpa.20222
21. Folstad I, Karter, AJ. Parasites, bright males, and the immunocompetence handicap. Am Nat. 1992;139(3):603-622.
22. Muehlenbein MP, Bribiescas RG. Testosterone-mediated immune functions and male life histories. Am J Hum Biol. 2005;17:527-558. doi:10.1002/ ajhb.20419
23. Ellison PT, Bribiescas RG, Bentley, et al. Population variation in age-related decline in male salivary testosterone. Hum Reprod. 2002;17:3251-3253. doi:10.1093/humrep/17.12.3251
24. Bribiescas R. Testosterone levels among Ache hunter-gatherer men: A functional interpretation of population variation among adult males. Hum Nat. 1996;7:163-188. doi:10.1007/BF02692109
25. Trumble BC, Cummings D, von Rueden C, et al. Physical competition increases testosterone among Amazonian forager-horticulturalists: a test of the 'challenge hypothesis'. Proc R Soc B: Biol Sci. 2012;279(1739):2907-2912. doi:10.1098/rspb.2012.0455
26. Alvarado LC. Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men. Am J Hum Biol. 2010;22(4):449-455. doi:10.1002/ajhb.21016
27. Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World J Urol. 2011;29:171-178. doi:10.1007/s00345-010-0638-z
28. Howrey BT, Kuo Y-F, Lin Y-L, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. 2013;68:56-61. doi:10.1093/ gerona/gls135
29. Wolf AM, Schorling JB. Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent. J Gerontol A Biol Sci Med Sci. 1998;53A:M195-M200. doi:10.1093/gerona/53A.3.M195
30. Prassopoulos P, Charoulakis N, Anezinis P, Daskalopoulos G, Cranidis A, Gourtsoyiannis N. Suprapubic versus transrectal ultrasonography in assessing the volume of the prostate and the transition zone in patients with benign prostatic hyperplasia. Abdom Imaging. 1996;21:75-77. doi:10.1007/s002619900017
31. Huang Foen Chung JWNC, de Vries SH, Raaijmakers R, Postma R, Bosch JLHR, van Mastrigt R. Prostate volume ultrasonography: The influence of transabdominal versus transrectal approach, device type and operator. Eur Urol. 2004;46:352-356. doi:10.1016/j.eururo.2004.05.002
32. Hricak H, Jeffrey RB, Dooms G, Tanagho E. Evaluation of prostate size: a comparison of ultrasound and magnetic resonance imaging. Urol Radiol. 1987;9:1-8. doi:10.1007/bf02932619
33. Bienz M, Hueber P-A, Al-Hathal N, et al. Accuracy of transrectal ultrasonography to evaluate pathologic prostate weight: correlation with various prostate size groups. Urology. 2014;84:169-174. doi:10.1016/j.urology. 2014.02.022
34. Loeb S, Han M, Roehl KA, Antenor JOAV, Catalona WJ. Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. J Urol. 2005;173:63-65. doi:10.1097/01. ju.0000145883.01068.5f
35. Garraway WM, Lee RJ, Collins GN. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469-471. doi:10.1016/0140-6736(91)90543-X
36. Huh JS, Kim YJ, Kim SD. Prevalence of Benign Prostatic Hyperplasia on Jeju Island: Analysis from a Cross-sectional Communitybased Survey. World J Mens Health. 2012;30:131-137. doi:10.5534/ wjmh.2012.30.2.131
37. Turkbey B, Huang R, Vourganti S, et al. Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU Int. 2012;110:1642-1647. doi:10.1111/j.1464-410X.2012. 11469.x
38. Blanker MH, Groeneveld FPMJ, Prins A, Bernsen RMD, Bohnen AM, Bosch JLHR. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: The Krimpen study of male urogenital tract problems and general health status. BJU Int. 2000;85:665-671. doi:10.1046/j.1464-410x.2000.00570.x
39. Collins GN, Lee RJ, McKelvie GB, Rogers ACN, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol. 1993;71:445-450. doi:10.1111/j.1464-410X.1993. tb15990.x
40. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161:1174-1179. doi:10.1016/S0022-5347(01)61621-5
41. Gu F. Changes in the prevalence of benign prostatic hyperplasia in China. Chin Med J (Engl). 1997;110:163-166.
42. Campbell B. High rate of prostate symptoms among Ariaal men from Northern Kenya. Prostate. 2005;62:83-90. doi:10.1002/pros.20120
43. Jin B, Turner L, Zhou Z, Zhou E, Handelsman D. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab. 1999;84:3613-3619. doi:10.1210/jcem.84.10.6041
44. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370:89-93. doi:10.1016/j.cca.2006.01.019
45. Boyle P, Lawrence Gould A, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48:398-405. doi:10.1016/S0090-4295(96)00353-6
46. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99:835-842. doi:10.1210/jc.2013-3570
47. Nesse RM, Stearns SC, Omenn GS. Medicine needs evolution. Science. 2006;311:1071. doi:10.1126/science.1125956
48. Kirkwood TB, Rose MR. Evolution of senescence: late survival sacrificed for reproduction. Philos Trans R Soc Lond B Biol Sci. 1991;332:15-24. doi:10.1098/rstb.1991.0028
49. Williams GC. Pleiotropy, Natural Selection, and the Evolution of Senescence. Evolution, 1957;11: 398-411.